X‑Chem Announces Achievement of Milestone In Orexia Collaboration
Waltham, Mass – July 22, 2020 – X-Chem, Inc. (X-Chem), the global leader in DNA-encoded small molecule library screening and drug discovery, announced today that it has met a key…
Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease
WALTHAM, Mass. – June 11, 2020 – X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced…
GHO Capital Acquires X‑Chem, the Leading Provider of DNA-Encoded-Library-Mediated Drug Discovery Services
London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (GHO), the European specialist investor in healthcare, announces the acquisition of X-Chem, Inc. (X-Chem), the industry-leading provider of DNA-Encoded…
X‑Chem Announces Licensing of a Drug Discovery Program to Otsuka
Waltham, Mass – May 20, 2020 – X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation…
ALK-Abelló and X‑Chem Announce Drug Discovery Collaboration
WALTHAM, Mass. – February 5, 2019 - X-Chem, Inc. (X-Chem), a privately held biotechnology company focused on applying its next-generation, industry-leading DNA-Encoded library (DEXTM) drug discovery platform to the generation…
ZebiAI Therapeutics, Inc. and X‑Chem Enter into Strategic Agreement to Enable Validation of Novel Therapeutic Targets and Acceleration of Drug Candidate Discovery
New venture capital-backed artificial intelligence company to utilize X-Chem’s leading DNA encoded library screening service WALTHAM, Mass. – ZebiAI Therapeutics, Inc. and X-Chem, Inc., both of Waltham, MA, and privately…